Suppression of myoclonus in SCA2by Piracetam

Anna De Rosa, Pasquale Striano, Fabrizio Barbieri, Arturo de Faco, Carlo Rinaldi, Tecla Tucci, Salvatore Striano, Alessandro Filla, Giuseppe De Michele

Research output: Contribution to journalArticle


We report on a 30-year-old patient with advanced cerebellar degeneration due to SCA2. He presented with severe myoclonus, which was resistant to conventional therapy and dramatically improved after administration of 12-18 gm/die piracetam. Piracetam may be considered in the treatment of refractory myoclonus in spinocerebellar degenerations.

Original languageEnglish
Pages (from-to)116-118
Number of pages3
JournalMovement Disorders
Issue number1
Publication statusPublished - Jan 2006


  • Myoclunus
  • Nootropic drugs
  • Piracetam
  • SCA2

ASJC Scopus subject areas

  • Clinical Neurology
  • Neuroscience(all)

Fingerprint Dive into the research topics of 'Suppression of myoclonus in SCA2by Piracetam'. Together they form a unique fingerprint.

  • Cite this

    De Rosa, A., Striano, P., Barbieri, F., de Faco, A., Rinaldi, C., Tucci, T., Striano, S., Filla, A., & De Michele, G. (2006). Suppression of myoclonus in SCA2by Piracetam. Movement Disorders, 21(1), 116-118.